Zengjun Li

机构：Second Military Medical University, West China Medical Center of Sichuan University, Naval University of Engineering, Changhai Hospital, Shandong First Medical University · ORCID：0000-0003-0787-8089

发表论文 324 篇 · 总被引 2210 次 · h-index 26

代表论文

• Integrative multi-omics of esophageal squamous cell carcinoma reveals immune alterations and lactylation-driven mechanisms in metastatic progression (2026 · Molecular Cancer)
• Association between expanded HIV testing and late diagnosis in older adults with HIV: evidence from southwest China (2026 · AIDS)
• Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China (2025 · EClinicalMedicine)
• Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial (2025)
• Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial (2025)
• Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial (2025)